How automated proofreading supports FDA, EMA, and 21 CFR Part 11 compliance

If you’re checking whether a specific proofreading tool holds up against FDA and EMA requirements, you’ve likely already ruled out “does this category of software exist”, you’re past that, and into “does this one work for my regulatory framework.” This piece answers that directly, including the question we get asked most often by name: how Schlafender Hase’s TVT specifically supports 21 CFR Part 11.

Key takeaways

• Automated proofreading supports FDA and EMA labeling requirements by providing the validated, auditable comparison step both regulators expect, not by carrying a certification of its own, since no software is “FDA-approved.”
• 21 CFR Part 11 governs how electronic records and signatures must be handled, with an emphasis on validation, audit trails, and record integrity; it applies to any electronic review or approval step in the labeling process.
• TVT facilitates compliance with FDA 21 CFR Part 11 and EMA Annex 11, is validated prior to every release, and ships with an IQ/OQ validation package customers can use to validate it in their own environment
• EMA-specific formats (QRD, SPL, SPM, FHIR XML) are supported directly, which matters more as e-labeling (ePI) adoption grows across markets.

How do automated proofreading tools support FDA and EMA labeling requirements?

They provide the validated, auditable comparison step both regulators expect: checking every label, leaflet, and artwork version against the last approved one, and generating a record of what was checked, by whom, and against what.

On the FDA side, that means supporting 21 CFR Part 201 (prescription drug labeling content), working within 21 CFR Part 211 (manufacturing controls), and — where reviews and approvals happen electronically — meeting 21 CFR Part 11’s requirements for electronic records and signatures. Our breakdown of FDA guidelines for pharmaceutical packaging artwork covers how those parts apply specifically to artwork review.

On the EMA side, it means supporting the formats EMA submissions actually run on — QRD templates, SPC/SmPC content, and pack leaflets — and meeting the equivalent electronic-records standard, Annex 11.

Worth being precise about what “support” means here: no proofreading software is FDA-approved or EMA-approved. Approval applies to the drug or device, not the verification tool used to check its labeling. What a tool like this does is give your team the validated, documented comparison step that makes your labeling process defensible when a regulator asks how you know it’s accurate. Our regulatory guidelines for labeling in pharma piece goes deeper on that distinction.

What is 21 CFR Part 11, and why does it matter for labeling and artwork review?

21 CFR Part 11 is the FDA rule governing electronic records and electronic signatures, it sets requirements for validation, audit trails, and record integrity wherever a company chooses to handle those electronically instead of on paper.

For labeling specifically, that reach is broad: any electronic review, comment, or sign-off step in your artwork or labeling process — a proofreading comparison, a QA approval, a change-control record — falls under it the moment it’s electronic. That’s why the compliance conversation around proofreading software isn’t really about the software being “Part 11 compliant” in the abstract. It’s about whether the records that software generates would hold up as valid electronic records if a regulator asked to see them.

How does Schlafender Hase support 21 CFR Part 11 compliance in its proofreading software?

TVT facilitates compliance with FDA 21 CFR Part 11 and EMA Annex 11 in three concrete ways.

Validation. Every version of TVT is validated prior to release, and for companies that need to validate it independently in their own environment, we provide a validation package with IQ and OQ test cases and a protocol that replicates our own validation process — most customers complete it in 1–2 days, with support from our team available if needed.

Audit trail, generated automatically. Every comparison produces a record of what was checked, what was flagged, and what decision was made — captured as a byproduct of normal use, not something a team has to reconstruct after the fact. Configurable report settings let you control exactly what gets included and how it’s timestamped.

Sign-off confidence. Regulatory teams using TVT report the practical effect of this most directly. As Pharmanovia’s Artwork Manager put it: “Since implementing TVT, the Regulatory team is a lot more confident in approving an artwork once they have reviewed the report, since they have the 100% security that the text matches whatever is approved by the health authority.”

For the deeper mechanics of how this fits into a validated environment — including how TVT integrates with artwork management and regulatory platforms rather than sitting outside them — see the hidden cost of getting content verification wrong, and for a plain look at what to expect from automated proofreading generally, what is automated proofreading in regulated industries? Not every tool marketed this way handles validation and audit trails the same way — what most proofreading software gets wrong about compliance is worth reading before assuming they do.

EMA-specific considerations: QRD templates, multilingual leaflets, and e-labeling (ePI)

QRD templates set the structure EMA expects pack leaflets and SmPCs to follow, and consistency across the markets a product ships in is one of the most common places that structure breaks down. TVT supports QRD, SPL, and SPM submission formats directly, and automatically excludes QRD template section headers from comparison, so a review isn’t flagging boilerplate structure as a deviation.

Multilingual pack leaflet verification matters just as much here as it does on the FDA side — a leaflet that’s accurate in the source language but drifts in translation is still non-compliant. TVT compares translated content against the source regardless of language, which is the same capability our pharmaceutical labeling workflow piece walks through in more detail.

E-labeling is the area moving fastest. As electronic product information (ePI) adoption grows across EU markets, FHIR-based structured content is becoming the format regulatory teams need to verify, not just the printed leaflet. TVT supports FHIR XML documents directly. If your team is building toward ePI, our FHIR-based ePI playbook and Risk 3 in our 2026 regulatory compliance risks piece are the two best next stops.

What “audit-ready” looks like day to day

In practice, it’s less dramatic than the phrase suggests — that’s the point. It means every comparison a reviewer runs produces a report showing exactly what was checked, what was flagged, and what was accepted or rejected, without anyone stopping to document it separately. It means a QA sign-off has something specific behind it — a report tied to a version, not just a reviewer’s word that they read it closely. And it means that if an inspector asks how a particular change was verified six months ago, the answer is a lookup, not a reconstruction project.

That’s the shift Pharma 5’s Regulatory Affairs team described after implementing TVT: “Now I have more certainty when I sign off a document.” Confidence at the point of sign-off is really what all of this is building toward — the audit trail is what makes that confidence defensible later.